A new organisation that aims to help move digital therapeutics into the medical mainstream by broadening their understanding, adoption, and integration has been launched.
The Digital Therapeutics Alliance’s founding members include Voluntis, Propeller Health and Akili Interactive, with the latter’s video game ADHD treatment expected to be submitted for FDA approval in 2018.
Akili CEO Eddie Martucci said: “Digital therapeutics are re-writing our definition of medicine. It’s critical that industry, academia, government, and the medical community work together in the next phase of medical adoption.”
“We’re excited to drive this effort alongside other leaders who share our dedication to rigorous clinical validation and organisational excellence in product development. It is truly a new class of medicine.”
Working with partners such as patients, healthcare providers, payers and pharma firms, the DTA will work on real world evidence studies, regulatory frameworks and create repositories of industry data and analyses.
The Alliance categorises digital therapeutics, or DTx, products as those requiring regulatory approval as a medical device, are integrated into clinical practice and which are tailored to patients’ clinical needs, goals and lifestyles.
Pierre Leurent, CEO at Voluntis, said: “Digital therapeutics are at the forefront of a new era in healthcare. As the entire industry prepares for what’s next, we are excited to represent digital therapeutics in this rapidly evolving environment, working with regulators, patient advocacy groups, providers, payers, and manufacturers.”
Following its formation the Digital Therapeutics Alliance formed a strategic partnership with the Personal Connected Alliance – which Lilly signed up to in earlier this year – to further establish digital therapeutics.
